Predict your next investment

Venture Capital
gra.org

See what CB Insights has to offer

Investments

6

Funds

1

About Georgia Research Alliance Venture Fund

Georgia Research Alliance Venture Fund is a venture capital firm based out of Atlanta, Georgia.

Georgia Research Alliance Venture Fund Headquarter Location

191 Peachtree Street, NE Suite 849

Atlanta, Georgia, 30303,

United States

(404)332-9770

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Georgia Research Alliance Venture Fund News

Lucid Scientific Secures $3 Million in Series Seed Financing Led by Dynamk Capital

Oct 22, 2020

October 1, 2020 in production, customer success, and direct sales to meet growing demand. Lucid Scientific, the biotechnology tools company that develops and manufactures RESIPHER, announced the completion of a $3 million Series Seed financing led by Dynamk Capital. Additional participants include Lucid’s original investor base and the Georgia Research Alliance’s Venture Fund, bringing Lucid’s total funding to date to approximately $4.5 million. Lucid is a member company in the Advanced Technology Development Center’s ATDC Accelerate portfolio. Proceeds from this round will help the company aggressively expand production, sales and marketing, as well as broaden product development. Dynamk Capital Managing Partner Gustavo Mahler, Ph.D., will join Lucid’s Board of Directors. “Lucid’s platform provides a novel, affordable and easy to use technology for continuous monitoring of cell culture plates, providing a highly valuable tool for research and development activities” Mahler said. “We look forward to helping Lucid expand the commercialization of their R&D solutions.” The financing accelerates exceptional momentum for Lucid which launched its RESIPHER product line earlier in the Spring of 2020. RESIPHER provides researchers with valuable insights into cellular metabolism that are of central importance for a wide range of therapeutic applications and drug safety considerations. RESIPHER converts standard cell culture plates into smart hand-held readers that sense real-time metabolic changes in response to potential therapeutics. This data significantly accelerates the basic research cycle by closing the gap between performing experiments and gaining actionable insight. The company has productized its patented technology and built an early customer base that includes top research laboratories. In 2020, Lucid doubled in size and formed a distribution partnership with the Baker Company, a global leader and supplier of anaerobic and modified atmosphere solutions. “This financing enables Lucid to dramatically expand access to RESIPHER for basic researchers and the drug discovery teams whose work directly impacts human health,” said Walker Inman, Ph.D., president and CEO of Lucid Scientific. “We are thrilled to have Gustavo and Dynamk join our team, as they provide a wealth of experience growing life science tools companies and help position Lucid to achieve our goals.” About Lucid Scientific Lucid Scientific (lucidsci.com) is a biotechnology tools company working to accelerate drug discovery and basic biological research by providing systems for real-time cellular analysis. Originally developed at MIT, Lucid’s patented RESIPHER system monitors cellular metabolism via non-invasive optical sensors, streaming information to researchers in real-time via a collaborative web platform. The information provided by Lucid’s systems saves time and enhances value to researchers performing millions of experiments annually. Headquartered in Atlanta, GA at the Advanced Technology Development Center (ATDC), Lucid is supported by public and private sources including Dynamk Capital and the GRA Venture Fund. For more information, visit lucidsci.com . About Dynamk Capital Dynamk Capital is a growth equity and venture capital firm focused on life sciences industrials. Dynamk’s investment strategy is centered on identifying companies developing disruptive technologies, tools, and services that enable the full biopharma continuum across discovery, development, and manufacturing of biotherapeutics, including cell & gene therapies and vaccines. Please visit  dynamk.vc for more information. About GRA Venture Fund GRA Venture Fund is a public-private venture capital fund investing in research-driven, Georgia-based startup companies. The Fund makes seed, early-stage and mid-stage investments in companies. Fund investors are the State of Georgia, private individuals, corporations and foundations. For more information, visit graventurefund.org .

Georgia Research Alliance Venture Fund Investments

6 Investments

Georgia Research Alliance Venture Fund has made 6 investments. Their latest investment was in Lucid Scientific as part of their Seed VC on September 9, 2020.

CBI Logo

Georgia Research Alliance Venture Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/22/2020

Seed VC

Lucid Scientific

$3.57M

Yes

5

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/22/2020

Round

Seed VC

Other Investors

Other Investors

Other Investors

Other Investors

Company

Lucid Scientific

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3.57M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

10

10

10

10

Georgia Research Alliance Venture Fund Fund History

1 Fund History

Georgia Research Alliance Venture Fund has 1 fund, including GRA Venture Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/3/2015

GRA Venture Fund

Early-Stage Venture Capital

$25M

1

Closing Date

8/3/2015

Fund

GRA Venture Fund

Fund Type

Early-Stage Venture Capital

Status

Amount

$25M

Sources

1

Georgia Research Alliance Venture Fund Team

2 Team Members

Georgia Research Alliance Venture Fund has 2 team members, including current Managing Director, Diana M. Murphy.

Name

Work History

Title

Status

Diana M. Murphy

Managing Director

Current

C. Michael Cassidy

Chief Executive Officer, President

Former

Name

Diana M. Murphy

C. Michael Cassidy

Work History

Title

Managing Director

Chief Executive Officer, President

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.